Influenza Vaccine Market by Vaccine Type (Inactivated, Live Attenuated, Recombinant), Age Group (Adolescent Vaccination, Adult Vaccination, Infant Vaccination), Administration Route, Distribution Channel - Global Forecast 2024-2030

Influenza Vaccine Market by Vaccine Type (Inactivated, Live Attenuated, Recombinant), Age Group (Adolescent Vaccination, Adult Vaccination, Infant Vaccination), Administration Route, Distribution Channel - Global Forecast 2024-2030


The Influenza Vaccine Market size was estimated at USD 7.92 billion in 2023 and expected to reach USD 8.61 billion in 2024, at a CAGR 9.01% to reach USD 14.49 billion by 2030.

Global Influenza Vaccine Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Influenza Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Influenza Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Influenza Vaccine Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, BioDiem, BiondVax Pharmaceuticals Ltd., Bristol-Myers Squibb Company, CanSino Biologics Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Eurocept Group, Fluart Innovative Vaccines Kft., Gamma Vaccines Pty Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus GmbH, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Swedish Orphan Biovitrum AB.

Market Segmentation & Coverage

This research report categorizes the Influenza Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Vaccine Type
Inactivated

Live Attenuated

Recombinant

Age Group
Adolescent Vaccination

Adult Vaccination

Infant Vaccination

Administration Route
Intramuscular

Intranasal

Oral

Distribution Channel
Government Medical Office

Hospital & Clinic

Retail Pharmacy

Urgent Care Unit

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Influenza Vaccine Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Influenza Vaccine Market?
3. What are the technology trends and regulatory frameworks in the Influenza Vaccine Market?
4. What is the market share of the leading vendors in the Influenza Vaccine Market?
5. Which modes and strategic moves are suitable for entering the Influenza Vaccine Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Influenza Vaccine Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Respiratory Disorders
5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
5.1.1.4. Government Initiatives Supporting Respiratory Health
5.1.2. Restraints
5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
5.1.3. Opportunities
5.1.3.1. Increasing R&D Expenditure by Leading Market Players
5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
5.1.4. Challenges
5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Influenza Vaccine Market, by Vaccine Type
6.1. Introduction
6.2. Inactivated
6.3. Live Attenuated
6.4. Recombinant
7. Influenza Vaccine Market, by Age Group
7.1. Introduction
7.2. Adolescent Vaccination
7.3. Adult Vaccination
7.4. Infant Vaccination
8. Influenza Vaccine Market, by Administration Route
8.1. Introduction
8.2. Intramuscular
8.3. Intranasal
8.4. Oral
9. Influenza Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Government Medical Office
9.3. Hospital & Clinic
9.4. Retail Pharmacy
9.5. Urgent Care Unit
10. Americas Influenza Vaccine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Influenza Vaccine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.
10. South Korea
11.
11. Taiwan
11.
12. Thailand
11.
13. Vietnam
12. Europe, Middle East & Africa Influenza Vaccine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.
10. Nigeria
12.
11. Norway
12.
12. Poland
12.
13. Qatar
12.
14. Russia
12.
15. Saudi Arabia
12.
16. South Africa
12.
17. Spain
12.
18. Sweden
12.
19. Switzerland
12.
20. Turkey
12.
21. United Arab Emirates
12.
22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. AstraZeneca PLC
14.1.3. Bayer AG
14.1.4. BioDiem
14.1.5. BiondVax Pharmaceuticals Ltd.
14.1.6. Bristol-Myers Squibb Company
14.1.7. CanSino Biologics Inc.
14.1.8. Daiichi Sankyo Company, Limited
14.1.9. Emergent BioSolutions Inc.
14.1.
10. Eurocept Group
14.1.
11. Fluart Innovative Vaccines Kft.
14.1.
12. Gamma Vaccines Pty Ltd
14.1.
13. GlaxoSmithKline PLC
14.1.
14. Johnson & Johnson
14.1.
15. Merck & Co., Inc.
14.1.
16. Pfizer Inc.
14.1.
17. Sanofi S.A.
14.1.
18. Seqirus GmbH
14.1.
19. Serum Institute of India Pvt. Ltd.
14.1.
20. Sinovac Biotech Ltd.
14.1.
21. Swedish Orphan Biovitrum AB
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. INFLUENZA VACCINE MARKET RESEARCH PROCESS
FIGURE 2. INFLUENZA VACCINE MARKET SIZE, 2023 VS 2030
FIGURE 3. INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INFLUENZA VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. INFLUENZA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. INFLUENZA VACCINE MARKET DYNAMICS
FIGURE 7. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
FIGURE 8. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 10. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2030 (%)
FIGURE 12. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings